ArticleThe oncologist2023

A Phase I Trial of the Dual MET Kinase/OCT-2 Inhibitor OMO-1 in Metastatic Solid Malignancies Including MET Exon 14 Mutated Lung Cancer.

Melinda A Pruis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.